Verstergaard has a reply on their website FWIW, can't vouch for it/just passing along: https://vestergaard.com/blogs/vestergaard-position-bloomberg-article-malaria-bed-nets-papua-new-guinea/
Hi Dustin :)
FWIW I also don't particularly understand the normative appeal of democratizing funding within the EA community. It seems to me like the common normative basis for democracy would tend to argue for democratizing control of resources in a much broader way, rather than within the self-selected EA community. I think epistemic/efficiency arguments for empowering more decision-makers within EA are generally more persuasive, but wouldn't necessarily look like "democracy" per se and might look more like more regranting, forecasting tournaments, etc.
Thanks MHR. I agree that one shouldn't need to insist on statistical significance, but if GiveWell thinks that the actual expected effect is ~12% of the MK result, then I think if you're updating on a similarly-to-MK-powered trial, you're almost to the point of updating on a coinflip because of how underpowered you are to detect the expected effect.
I agree it would be useful to do this in a more formal bayesian framework which accurately characterizes the GW priors. It wouldn't surprise me if one of the conclusions was that I'm misinterpreting GiveWell's current views, or that it's hard to articulate a formal prior that gets you from the MK results to GiveWell's current views.
FWIW I think I'm an example of Type 1 (literally, in Lorenzo's data) and I also agree that abstractly more of Type 2 would be helpful (but I think there are various tradeoffs and difficulties that make it not straightforwardly clear what to do about it).